Aobiome
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
160 Alewife Brook Pkwy 1008, Cambridge, ...Website
www.aobiome.comRevenue
$6.8 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Aobiome
AOBiome is a clinical-stage microbiome company specializing in the development of therapeutics for inflammatory conditions and central nervous system disorders. Their proprietary product candidates utilize Ammonia Oxidizing Bacteria (AOB) to restore critical biological processes and address significant clinical needs. The company has ongoing clinical programs targeting conditions such as acne, eczema, rosacea, and hypertension, as well as preclinical programs for pulmonary and gastrointestinal disorders. AOBiome aims to improve human health by repopulating beneficial bacteria on the skin to maintain a healthy immune system.Explore more
Aobiome Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Aobiome your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Aobiome recently announced quarterly report
Check if Aobiome has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Aobiome has new funding data
Product Launch: Get notified when Aobiome launches new products
Click to see if Aobiome had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Aobiome
Aobiome, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Aobiome is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Aobiome as Masked Content
Find 3 more new buyers
Compare Similar Companies to Aobiome
Compare insights from companies similar to Aobiome, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Aobiome is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Aobiome is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Aobiome.
Aobiome financials insights
Gather financial insights about Aobiome, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Private Equity
$630K
2014
Private Equity
$576K
2015
Private Equity
$2.5M
2017
Private Equity
$30M
Aobiome Tech Stack
A closer look at the technologies used by Aobiome
Most Recent Scoops
Person-Based
Person-Based
Left Company
Executive Move
Lauren Ambrogio, Chief Operating Officer, has left the organization.
Left Company
Executive Move
Left Company
Executive Move
Aobiome News & Media
AOB Pharma receives European Medicines Agency (EMA) positive decision on the pediatric investigation plan (PIP), supporting future development of B244 for the treatment of mild to moderate atopic dermatitis in children, adolescents, and adults in the European Union (EU)
B244, a first-in-class topical live biotherapeutic product, is currently planned for global Phase 3 development in mild to moderate atopic dermatitis and pruritus. EMA's Pediatric Committee (PDCO) agrees to AOBiome's PIP with a positive decision on September 10, 2025 and publishes in the...AOB Pharma reveals new metabolomic insights of B244, suggesting investigation of potential new avenues for treatment
AOB Pharma reveals new insights via metabolomic analysis of B244, supporting clinical readouts & suggesting investigation of potential new avenues for treatment CAMBRIDGE, MA, UNITED STATES, May 21, 2025 /EINPresswire.com/ -- AOB Pharma reveals new …USPTO Grants AOBiome Therapeutics Composition of Matter Patent for its Clinical Candidate B244
B244 has demonstrated clinical efficacy on therapeutic indications including: Atopic Dermatitis (Eczema) and Pruritus (Itch), and Acne Vulgaris (Acne) CAMBRIDGE, MA, UNITED STATES, October 9, 2024 /EINPresswire.com/ -- USPTO Grants AOBiome Therapeutics …AOB Pharma and Maruho enter into an Exclusive License Agreement for AOB Pharma's Topical Biologic B244 for the Treatment of Inflammatory Indications including Atopic Dermatitis in Japan
The license is exclusive for the territory of Japan and contains rights for future indications Maruho is responsible for conducting and bearing costs for development in Japan, which will be conducted jointly with AOB Pharma as part of a Global Phase 3 Study for Atopic Dermatitis...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Aobiome
Sign Up For FreeTo access detailed company insights
AOBiome is a clinical-stage microbiome company specializing in the development of therapeutics for inflammatory conditions and central nervous system disorders. Their proprietary product candidates utilize Ammonia Oxidizing Bacteria (AOB) to restore critical biological processes and address significant clinical needs. The company has ongoing clinic... Read More
